Nuvalent Receives U.S. FDA Breakthrough Therapy Designation for NVL-520
Go back to Nuvalent Receives U.S. FDA Breakthrough Therapy Designation for NVL-520| Nuvel Holdings, Inc. (NASDAQ: NUVL) | Delayed: 123.96 --0 (-0%) | |||||
|---|---|---|---|---|---|---|
| Previous Close | $123.96 | 52 Week High | $0.40 | |||
| Open | $123.96 | 52 Week Low | $0.14 | |||
| Day High | $123.96 | P/E | N/A | |||
| Day Low | $123.96 | EPS | $-0.56 | |||
| Volume | 81,190 | |||||
